A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data

Khyatiben Rana,1 Jessica Reid,1 Joshua N Rosenwasser,2 Todd Lewis,3 Mae Sheikh-Ali,4 Rushab R Choksi,1 Rebecca F Goldfaden1 1East Coast Institute for Research, Jacksonville, FL, USA; 2Lincoln Medical and Mental Health Center, Bronx, NY, USA; 3Baker-Gilmour Cardiovascular Institute, Jacksonville, FL,...

Full description

Bibliographic Details
Main Authors:	Rana K, Reid J, Rosenwasser JN, Lewis T, Sheikh-Ali M, Choksi RR, Goldfaden RF
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-09-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	Praluent Alirocumab PCSK9 PCSK9-inhibitor Cardiovascular Disease Atherosclerosis Dyslipidemia
Online Access:	https://www.dovepress.com/a-spotlight-on-alirocumab-in-high-cardiovascular-risk-patients-with-ty-peer-reviewed-article-DMSO

Similar Items

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients
by: Gianluigi Cuomo, et al.
Published: (2022-06-01)

Efficacy and safety of the use of alirocumab in real clinical practice
by: Viktoria A. Korneva, et al.
Published: (2023-01-01)

Effect of alirocumab on cataracts in patients with acute coronary syndromes
by: Gaspard Suc, et al.
Published: (2023-06-01)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
by: Joshua Choi, et al.
Published: (2017-07-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
by: Tamio Teramoto, et al.
Published: (2017-06-01)

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
by: A. E. Nikitin, et al.
Published: (2020-03-01)

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
by: Fairman KA, et al.
Published: (2017-08-01)

Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
by: Vanessa Bianconi, et al.
Published: (2023-09-01)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01)

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat
by: Hong-Fei Wang, et al.
Published: (2022-12-01)

Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease
by: Fei Gao, et al.
Published: (2022-05-01)

Short-Term Treatment with Alirocumab, Flow-Dependent Dilatation of the Brachial Artery and Use of Magnetic Resonance Diffusion Tensor Imaging to Evaluate Vascular Structure: An Exploratory Pilot Study
by: Thomas Metzner, et al.
Published: (2022-01-01)

The wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
by: Natalia Ilnicka, et al.
Published: (2023-09-01)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2021-03-01)

Intensification of lipid-lowering therapy in very high-risk patients: potential of combination with PCSK9 inhibitors
by: D. Yu. Sedykh, et al.
Published: (2022-07-01)

Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study
by: Thomas Metzner, et al.
Published: (2022-01-01)

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
by: Angela Dardano, et al.
Published: (2021-07-01)

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
by: Helen M. Colhoun, et al.
Published: (2020-02-01)

New Drugs for Treating Dyslipidemia: Beyond Statins
by: Chang Ho Ahn, et al.
Published: (2015-04-01)

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials
by: Kusha A. Mohammadi, et al.
Published: (2023-08-01)

Mortality Benefit of Alirocumab: A Bayesian Perspective
by: Christopher Labos, et al.
Published: (2019-10-01)

Insight into the Evolving Role of PCSK9
by: Mateusz Maligłówka, et al.
Published: (2022-03-01)

Low-density lipoprotein particles in atherosclerosis
by: Ya-Nan Qiao, et al.
Published: (2022-08-01)

Real-World Use of Alirocumab: Experience from a Large Healthcare Provider
by: Avishay Elis, et al.
Published: (2023-01-01)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
by: Julius L. Katzmann, et al.
Published: (2020-11-01)

Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
by: Ashraf Reda, et al.
Published: (2020-05-01)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023-12-01)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
by: Rahayu Zulkapli, et al.
Published: (2023-03-01)

An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a)
by: Jose A. Caparrós-Martín, et al.
Published: (2024-01-01)

New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01)

Genetics in familial hypercholesterolaemia – from genetic research to new guidelines
by: Edyta Kinga Prokop, et al.
Published: (2019-04-01)

The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus
by: Aleksandra Frątczak, et al.
Published: (2022-09-01)

Safety of PCSK9 inhibitors
by: Grzegorz Grześk, et al.
Published: (2022-12-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
by: Łukasz Wołowiec, et al.
Published: (2023-01-01)

PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk
by: Pere Rehues, et al.
Published: (2023-01-01)

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial
by: Shaun G. Goodman, et al.
Published: (2023-09-01)

Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review
by: Yoonkyung Chang, et al.
Published: (2023-04-01)